Imricor Medical Systems, Inc. (ASX: IMR) Submits NorthStar for CE Mark Approval
Imricor submits NorthStar for CE Mark approval and accelerates FDA submission, anticipating major advancements in cardiac procedures.
Category: Healthcare
Acrux Limited (ASX:ACR) Raises $1.34 Million from Share Purchase Plan
Acrux Limited (ASX:ACR) raises $1.34 million through its Share Purchase Plan to advance its pharmaceutical development pipeline.
Lumos Diagnostics (ASX:LDX) Commences FebriDx CLIA Waiver Study
Lumos Diagnostics announces the launch of the FebriDx CLIA Waiver study, aimed at improving antibiotic use with substantial support from BARDA.
Epsilon Healthcare Limited (ASX:EPN) Update on Growth and Strategy
Epsilon Healthcare Limited (ASX:EPN) outlines its ambitious targets and operational capabilities, aiming for $14M revenue growth.
Mesoblast Limited (ASX:MSB) Achieves FDA Approval for RYONCIL
Mesoblast Limited announces FDA approval of RYONCIL, the first MSC therapy for children with steroid-refractory acute graft versus host disease.
Amaero International Limited (ASX:3DA) Expands Production Capabilities
Amaero International Limited secures a third EIGA atomizer, bolstering production for advanced manufacturing, as part of a strategic investment of A$71 million.
Orthocell Limited (ASX:OCC) Submits FDA Application for Remplir™
Orthocell submits its FDA application for Remplir™, targeting the US nerve repair market, with clearance expected by April 2025.
Imugene Limited (ASX:IMU) Confirms $11 Million R&D Tax Refund
Imugene Limited (ASX:IMU) secures $11 million R&D tax refund to advance its immuno-oncology therapies.
EBR Systems, Inc. (ASX:EBR) Schedules FDA Pre-Approval Inspection
EBR Systems, Inc. announces a scheduled FDA Pre-Approval Inspection for its wireless cardiac pacing device, a pivotal step in regulatory progress.
Deep Yellow Limited (ASX:DYL) Reports Significant Ore Reserve Upgrade
Deep Yellow Limited announces an 18% increase in Ore Reserves at the Tumas Project, estimating a 30-year mine life.